Literature DB >> 12809701

Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry.

D Bridges1, A S C Rice, M Egertová, M R Elphick, J Winter, G J Michael.   

Abstract

In this study we used in situ hybridisation and double-labelling immunohistochemistry to characterise cannabinoid receptor 1 (CB(1)) expression in rat lumbar dorsal root ganglion (DRG) neurons.Approximately 25% of DRG neurons expressed CB(1) mRNA and displayed immunoreactivity for CB(1). Sixty-nine percent to 82% of CB(1)-expressing cells were also immunoreactive for neurofilament 200, indicative of myelinated A-fibre neurons, which tend to be large- and medium-sized DRG neurons (>600 microm(2)). Approximately 10% of CB1-expressing cells also expressed transient receptor potential vanilloid family ion channel 2 (TRPV2), the noxious heat-transducing channel found in medium to large lightly myelinated Adelta-fibre DRG neurons. Seventeen percent to 26% of CB(1)-expressing cells co-stained using Isolectin B4, 9-10% for calcitonin gene-related peptide and 11-20% for transient receptor potential vanilloid family ion channel 1 (TRPV1), predominantly markers of small non-myelinated C-fibre DRG neurons (<600 microm(2)). These findings suggest that whilst a wide range of DRG neuron phenotypes express CB(1), it is predominantly associated with myelinated fibres.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12809701     DOI: 10.1016/s0306-4522(03)00200-8

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  53 in total

1.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

2.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

Review 3.  Research progress in transient receptor potential vanilloid 1 of sensory nervous system.

Authors:  Da-Lu Liu; Wen-Ting Wang; Jun-Ling Xing; San-Jue Hu
Journal:  Neurosci Bull       Date:  2009-08       Impact factor: 5.203

Review 4.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

5.  A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons.

Authors:  Theodore J Price; Amol M Patwardhan; Christopher M Flores; Kenneth M Hargreaves
Journal:  Neuropharmacology       Date:  2005-04-01       Impact factor: 5.250

Review 6.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

7.  Cannabinoid modulation of cutaneous Adelta nociceptors during inflammation.

Authors:  Carl Potenzieri; Thaddeus S Brink; Cholawat Pacharinsak; Donald A Simone
Journal:  J Neurophysiol       Date:  2008-09-10       Impact factor: 2.714

Review 8.  The Role of the Endocannabinoid System in the Brain-Gut Axis.

Authors:  Keith A Sharkey; John W Wiley
Journal:  Gastroenterology       Date:  2016-04-29       Impact factor: 22.682

9.  The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain.

Authors:  M L Uhelski; D M Cain; C Harding-Rose; D A Simone
Journal:  Neuroscience       Date:  2013-05-11       Impact factor: 3.590

10.  Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Authors:  Theodore J Price; Amol Patwardhan; Armen N Akopian; Kenneth M Hargreaves; Christopher M Flores
Journal:  Br J Pharmacol       Date:  2004-03-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.